Samsung Bioepis

Samsung Bioepis Gets FDA Approval for Biosimilar of J&J’s Stelara
BioSpace
Mon, 07/1/24 - 09:58 pm
Samsung Bioepis
FDA
Pyzchiva
biosimilars
JNJ
Stelara
Novartis, Roche unit and others face Italy antitrust probe over eye drug
Reuters
Thu, 06/6/24 - 11:34 am
Novartis
Roche
Genentech
Italy
antitrust
Biogen
Samsung Bioepis
Byooviz
Samsung joins biosimilar race for Merck & Co.'s Keytruda blockbuster
First Word Pharma
Thu, 02/22/24 - 11:43 am
Samsung Bioepis
Merck
biosimilars
Keytruda
clinical trials
FDA Accepts sBLA for Interchangeability Designation for Humira biosimilars
Dermatology Times
Wed, 11/8/23 - 09:55 pm
Samsung Bioepis
Organon
FDA
AbbVie
Humira
biosimilars
Sandoz to Commercialize Samsung Bioepis’ Biosimilar to J&J’s Stelara
BioSpace
Tue, 09/12/23 - 10:40 am
Sandoz
Samsung Bioepis
biosimilars
JNJ
Stelara
Biogen looks at selling biosims unit to longtime ally Samsung Bioepis: reports
Fierce Pharma
Thu, 08/3/23 - 09:59 am
Biogen
biosimilars
M&A
Samsung Bioepis
Biogen, Samsung Bioepis launch ranibizumab-nuna in US
Ophthalmology Today
Fri, 06/3/22 - 09:11 am
Biogen
Samsung Bioepis
ranibizumab
ranibizumab-nuna
biosimilars
Roche
Lucentis
retinal disease
Takeover-driven resurgence fails to materialize for biotech
EP Vantage
Thu, 04/14/22 - 10:41 am
M&A
AbbVie
Biocon
Biogen
Biohaven
GSK
Halozyme Therapeutics
Samsung Bioepis
UCB
Viatris
Biogen to sell stake in Samsung Bioepis JV for up to $2.3bn
Biopharma Reporter
Fri, 01/28/22 - 10:07 am
Biogen
biosimilars
Samsung Bioepis
FDA approves first biosimilar to top-selling eye drug Lucentis
BioPharma Dive
Mon, 09/20/21 - 10:55 pm
FDA
biosimilars
Lucentis
age-related macular degeneration
Byooviz
Biogen
Samsung Bioepis
FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar
Pharmaforum
Thu, 11/19/20 - 10:33 am
Novartis
Genentech
Lucentis
biosimilars
Samsung Bioepis
Biogen
FDA
WHO Prequalifies its First Biosimilar
RAPS.org
Thu, 12/19/19 - 06:01 pm
WHO
biosimilars
Samsung Bioepis
Ontruzant
Roche
Herceptin
breast cancer
DEAL WATCH: Biosimilars, Biosimilars and More Biosimilars
Big Molecule Watch
Sun, 11/10/19 - 07:55 pm
biosimilars
Henlius
Ascentage
rituximab
Bioeq
Alvotech
Coherus
Biogen
Samsung Bioepis
Biogen signs marketing deal for two ophthalmology biosimilars
Pharmaforum
Thu, 11/7/19 - 10:16 am
Biogen
ophthalmology
biosimilars
Europe
Japan
Samsung Bioepis
SB11
SB15
Lucentis
Eylea
Biogen ups investment in biosimilars
Marketwatch
Wed, 11/6/19 - 10:20 am
Biogen
biosimilars
Samsung Bioepis
Samsung Bioepis announces phase 3 results of SB8, Bevacizumab biosimilar candidate, at ESMO 2019 Congress
Pharmaceutical Business Review
Fri, 09/27/19 - 09:34 am
ESMO
Samsung Bioepis
clinical trials
SB8
biosimilars
bevacizumab
non-small cell lung cancer
FDA-approved Humira copycat from Merck, Samsung Bioepis will wait 4 years to launch
Endpoints
Wed, 07/24/19 - 10:07 am
Merck
Samsung Bioepis
FDA
Humira
AbbVie
drug launches
biosimilars
Samsung Bioepis CEO urges patience as US biosimilar market lags
BioPharma Dive
Wed, 06/26/19 - 12:04 pm
biosimilars
Samsung Bioepis
Celltrion and Samsung duel shaping up as both pledge billions of dollars to biologics
Fierce Pharma
Fri, 05/17/19 - 07:28 pm
biologics
South Korea
Celltrion
Samsung Bioepis
FDA Approves 19th Biosimilar, 2nd for Enbrel
RAPS.org
Fri, 04/26/19 - 07:38 pm
FDA
Samsung Bioepis
Eticovo
biosimilars
Amgen
Enbrel

Pages